tiprankstipranks
FDA Joint Committee Meeting
The Fly

FDA Joint Committee Meeting

The Nonprescription Drugs Advisory Committee (NDAC) and Anesthetic & Analgesic Drug Products Advisory Committee (AADPAC) discusses Emergent BioSolutions’ supplemental New Drug Application, sNDA 208411/S-006 for NARCAN (naloxone hydrochloride) nasal spray, 4 mg/0.1 mL, proposed for nonprescription treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in a meeting being held on February 15 at 9 am. Webcast Link

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on EBS:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles